Annual Report to Shareholders
Released
Released
Announcement PDF
Annual
Report
2023
ASX: RCE, FSE: R9Q
Contents
1
Business Highlights
2
Letter from the Chairman
5
Letter from the CEO
8
Overview of Clinical Activities
9
Intravenous Programs
10
Topical Programs
11
Pre-Clinical
12 Conference Engagement
13 Board of Directors and Key Management Personnel
15 Financial Report
74 Corporate Directory
Recce Pharmaceuticals Ltd (ASX: RCE,
FSE: R9Q) is developing a new class of
Synthetic Anti-Infectives designed to
address the urgent global health problems
of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes
three patented, broad-spectrum, synthetic
polymer anti-infectives: RECCE® 327 as
an intravenous and topical therapy that
is being developed for the treatment of
serious and potentially life-threatening
infections due to Gram-positive and
Gram-negative bacteria including their
superbug forms; RECCE® 435 as an oral
therapy for bacterial infections; and
RECCE® 529 for viral infections. Through
their multi-layered mechanisms of action,
Recce’s anti-infectives have the potential
to overcome the hypercellular mutations
of bacteria – the challenge of all existing
antibiotics to date.
The US Food and Drug Administration
has awarded RECCE® 327 Qualified
Infectious Disease Product designation
under the Generating Antibiotic Initiatives
Now (GAIN) Act – labelling it for Fast
Track Designation, plus 10 years of market
exclusivity post approval. Further to
this designation, RECCE® 327 has been
included on The Pew Charitable Trusts
Global New Antibiotics in Development
Pipeline as the world’s only synthetic
polymer and sepsis drug candidate in
development. RECCE® 327 is not yet
market approved for use in humans with
further clinical testing required to fully
evaluate its safety and efficacy.
Recce wholly owns its automated
manufacturing, which is supporting
present clinical trials. Recce’s anti-infective
pipeline seeks to exploit the unique
capabilities of its technologies targeting
synergistic, unmet medical needs.
Business Highlights
Below are listed the main corporate developments for the
FY23 period between July 2022 and June 2023.
Commercial and Operational
Regulatory
Recce delivered Opening R&D Address at World
Anti-Microbial Resistance Congress 2022
RECCE® Trademark registered in Hong Kong
and Israel
Western Australian Government Sponsorship received
for BIO Korea 2023
New Family 4 patent granted for RECCE®
Anti-Infectives in Australia
Alistair McKeough appointed to Board of Directors
Dr John Prendergast appointed as Executive Chairman
Total of A$4.31m received from R&D Rebate Payments
Anti-Infective Research Unit established at Murdoch
Children’s Research Institute
Pre-Clinical and Clinical
RECCE® 327 (R327) shown to significantly reduce
SARS-CoV-2 in hamsters
Positive safety data from 7th cohort of Phase I clinical
trial evaluating RECCE® 327 intravenous formulation
in healthy male volunteers
Diabetic Foot Infections (DFI)
– Ethics Approval received to start Phase I/II DFI study
– Outpatient nurses appointed for DFI Phase II study
Urinary Tract Infection (UTI)/Urosepsis
– CMAX Research Facility selected for Phase I/II Rapid
Infusion UTI/Urosepsis trial
– Site expansion and additional HREC approval received
for Phase I/II Rapid Infusion UTI/Urosepsis trial
– (Post FY23) First cohort dosed in RECCE® 327
Phase I/II Rapid Infusion UTI/Urosepsis clinical trial
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
– Human Research Ethics Approval (HREC) received
to start Phase I/II Rapid Infusion UTI/Urosepsis trial
1
Letter from the
Chairman
Dear Fellow Shareholders,
I am pleased to provide our annual report
and operating review for FY23 from which
we continue to lay solid foundations that will
support long-term sustainable growth for
shareholders.
This year marks seven years
since Recce’s listing on the
Australian Securities Exchange,
an occasion that gave me cause
to reflect upon the Company’s
remarkable journey so far.
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
2
Dr John Prendergast
Executive Chairman
This year marks seven years since Recce’s
listing on the Australian Securities Exchange,
an occasion that gave me cause to reflect upon
the Company’s remarkable journey so far.
Thanks to the dedication of our team, Recce
is forging a path that recognises it as a global
leader in the field of anti-infectives. Recce is
leading the way towards new and transformative
therapeutics for treating severe infections.
Foundations for growth in place
While the Company's first years were focused on
pre-clinical activities, establishing manufacturing
capabilities and growing our clinical expertise,
this reporting period was a robust year for
Recce. We successfully completed a number
of important milestones, including the delivery
of comprehensive first safety data for our lead
compound, R327, in healthy volunteers, that
lays the foundation for the potential of R327
to become a first-line treatment for unmet
medical needs.
As the clinical safety data builds, and as the
potential to use R327 in a broader set of
indications and formulations grows, Recce has
worked tirelessly to prepare for the next round
of studies that will aim to accelerate R327's
development and bring this innovative therapy
to market. These upcoming studies include a
trial to determine the optimal intravenous dose
levels for the treatment of sepsis, urosepsis and
urinary tract infections, which have critical
unmet medical needs.
At the same time, our topical treatment
programs for burns and diabetic foot ulcer
infections continue to progress and are
attracting strong interest from industry-leading
clinicians and potential commercial partners
in Australia and overseas.
Several important pre-clinical programs
demonstrating the activity of our lead compound
against several World Health Organisation
priority pathogens, including Streptococcus
pneumoniae and Mycobacterium abscessus,
are all steadily advancing towards first-inhuman studies.
I am pleased to report that as a result of our
operational achievements and the favourable
Australian tax incentive on Research &
Development activities, Recce is well placed
to fund its progress towards the achievement
of a number of key clinical milestones over
the coming quarters.
A bright future
In the coming 12 months, we expect to expand
our clinical therapeutic programs with a number
of new Phase II studies. We expect to see
our manufacturing capability expanded and
our production facility in Sydney capable of
supplying our ongoing clinical trials.
Our pipeline of programs and growing in-house
capabilities ensure Recce maintains its leadership
position in the global anti-infective space – a
sector that has garnered increasing interest from
international investment and pharmaceutical
industries.
Recce has a clear vision for the future and the
team is focused on delivering on our priorities
to bring innovative anti-infectives to market,
delivering value to all our stakeholders and
shareholders.
Governance priorities
Another foundation for growth and the many
opportunities before us is our focus on bestpractice governance, which is always a major
focus of the Board.
The composition of the Board is always a priority.
We aim to have the right skills and expertise
to navigate our industry and the broader
environment.
In line with the planned expansion of our clinical
programs, the Board of Directors has been
refreshed with new appointments throughout
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
Financial and reputational strength to
transform Recce over the coming years
Thanks to its increasing international activities,
Recce is building momentum and garnering
broader attention as a leader in the field of
anti-infectives, resulting in opening new doors
with potential partners, be it pharmaceutical
companies or international and domestic
organisations. Highlighting this awareness
is the Company’s recent invitation to present
the opening R&D address at the prestigious
World Anti-Microbial Resistance Congress 2023.
We are also delighted to have been invited
by the US Defense Department to hold a
presentation on infectious diseases at the
2023 Military Health System Research
Symposium in August 2023.
3
the year as part of the Company’s ongoing
succession planning to ensure the skills and
experience is commensurate with Recce’s
growth and future focus.
The coming years present great opportunities for
our business to tackle one of the world’s biggest
healthcare challenges: the unprecedented threat
of antimicrobial resistance.
I am pleased to have welcomed Alistair
McKeough as Non-Executive Director. He brings
a wealth of legal expertise to complement the
diverse skills and experience of our Board. We
also welcomed Maggie Niewidok as our new
Company secretary.
Our mission at Recce is to impact this global
issue. I, along with James Graham, our Managing
Director and CEO, and the entire Recce team
look forward to pursuing this challenge with you.
Again, thank you for your most welcome
continued support.
Looking ahead
On behalf of the board, I would like to thank
James Graham, our CEO, the management team
and all our clinical and commercial partners,
for their personal commitment, dedication, and
contributions to the success of Recce this year.
Most assuredly, I would also like to thank our
shareholders for their ongoing support which
has been an important contribution to our
success.
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
4
John Prendergast
Chair
Letter from the
CEO
Dear Shareholders,
FY23 has been another significant year for
Recce, a transformational one. We completed
our first in-human safety and tolerability study
with excellent results and progressed to a Phase
I/II Rapid Infusion UTI/Urosepsis clinical trial.
Recce’s progress and success
this year is a direct reflection of
the focus and dedication of our
growing team combined with
the significant medical potential
of our new generation antiinfectives.
Our clinical progress confirms the robustness
of the safety profile of R327, the world’s first
new class of anti-infective with a novel and
differentiated Mechanism of Action in over 30
years. These very promising safety data are also
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
James Graham
Managing Director and Chief Executive Officer
As we work towards initiating our Phase II study
for R327 in UTI/Urosepsis and studies for our
new gel formulation of R327 in diabetic foot
ulcer and burn wound infections, we aim to have
data from a number of these programs in
FY 2024.
5
Recce’s clinical programs are
advancing towards a market
actively seeking new antibiotic
and anti-infective solutions.
Market awareness and demand
is evolving rapidly.
a major achievement and a sound foundation
for the many studies to now follow.
Recce’s progress and success this year is a direct
reflection of the focus and dedication of our
growing team combined with the significant
medical potential of our new generation of
anti-infectives.
Aside from the usual challenges of leading an
early-stage biotech, Recce has achieved all this
despite a global pandemic, geopolitical unrest
and instability in financial markets.
Our long-term opportunity for growth
The challenge for an opportunity-rich business
like Recce, seeking to commercialise high
value clinical assets with multiple therapeutic
applications globally, is to remain focused while
simultaneously building the broad foundations
for expansion into addressing major unmet
medical needs.
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
6
I believe we have delivered the right balance of
focus on near-term priorities and commitment
to long-term opportunities while maintaining
a lean and efficient organisation.
We continued to collaborate with a number of
highly qualified medical investigators in Australia
and expanded our network around the world,
most notably in the US with strong interest from
US Key Opinion Leaders, the US military as well
as industrial partners based in the US.
On a personal note, I am constantly inspired by
the conversations we have with patients with
drug-resistant infections and clinicians tasked
with treating these unmet medical needs;
witnessing the incredible potential for real-life
impact that our drug can have on those who
need it most.
Culture and values
Our ability to help improve the lives of people
facing the threat of antibiotic-resistant infections
is increasing every day, through our clinical trials
and special access programs.
This is where our people and our shareholders
can be incredibly proud. Recce’s progress
does not happen without a talented group
of committed people.
While our teams connect virtually and in person
across different offices and time zones, they
remain motivated and dedicated. Recce is
building a unique culture that will form a solid
foundation as we strive to address the global
health threat posed by antibiotic-resistant
superbugs.
Recce has demonstrated it can effectively
advance several clinical programs while
simultaneously building the necessary
commercial and clinical relationships to
support our future success.
An opportune time
Outlook
In the coming year we will focus on completing
the next phase of our clinical program while
building on the achievements of the previous
12 months.
In closing, I would like to thank the Recce team,
our shareholders, clinical partners and the many
who make it possible to deliver our strategy and
support our goal of bringing effective new antiinfective treatments to millions of people with
life-threatening infections and to protect the
health of communities everywhere.
Recce’s clinical programs are advancing
towards a market actively seeking new antibiotic
and anti-infective solutions. Market awareness
and demand is evolving rapidly.
Evidence of this came with the US House of
Representatives and Senate moving to revive
the PASTEUR Act in an effort to revitalise
antibiotic development in the US. PASTEUR,
which stands for Pioneering Antimicrobial
Subscriptions To End Upsurging Resistance,
has strong bipartisan support because of its
balanced approach to the development of
urgently needed new antibiotics and antifungals.
Every 15 minutes, a person in the United States
dies from an infection resistant to treatment with
existing antimicrobial drugs. Sepsis is the United
States’ most expensive condition in aggregate
to treat in the hospital, costing the healthcare
system US$57bn annually in inpatient costs.
Sepsis has even become the leading cause of
deaths in US hospitals and Recce is a potential
solution for this, with extremely promising
pre-clinical and clinical results for R327 in
that indication.
Recce is one of just a small group of global
companies solely dedicated to the development
and commercialisation of new antibiotic
solutions. The depth of our innovative pipeline
differentiates us and strengthens our position
in this dynamic and promising field of medical
innovation.
It is an exciting time to be a part of Recce as we
actively deliver on our clinical and operational
objectives.
James Graham
Managing Director and Chief Executive Officer
While pharmaceutical companies have mostly
stayed away from anti-infectives for the last
20 years, the strong medical need is driving
a resurgence of interest with a steady increase
in the number of large pharmaceutical
companies becoming more active in the
sector via acquisitions, partnerships and
collaborations over the past 12 months.
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
7
Overview of Clinical Activities
The Company has focused its efforts on progressing its clinical trials and
pre-clinical programs. Commercial, clinical and operational goals and
objectives were met, with key highlights being the conclusion of the Phase I
Intravenous clinical trial of R327 and the initiation of new clinical trials for
multiple routes of administration, including intravenous and topical.
Asset and
Route of Administration
R327 Intravenous
Indications
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Market
Serious/life threatening bacterial
infections including sepsis
Urinary tract infections
including urosepsis
Multidose, early stage, rapid
infusions sepsis efficacy study
R327 Topical
Wound infections including
infected burns
Diabetic Foot Ulcer Infections
Pre-Clinical Programs
Various routes of administration
Mycobacterium abscessus
Bacterial Sinusitis
Additional TBA
Financially, the Company has been able to remain
well-funded while delivering on multiple clinical
objectives. Supported by the Australian Government’s
Research and Development Tax Incentive, the
Company remains well placed to continue its
clinical progress into the next financial year.
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
8
Supporting clinical trials, the Anti-Infective Research
Unit that was established at Murdoch Children’s
Research Institute has continued to advance potential
pre-clinical indications by conducting high-quality
research at a world-leading medical R&D organisation.
Human Clinical Trials
Post FY23 (19 July, 2023) the Company announced
that independent examiners confirmed that the Phase
I clinical trial data review was complete and all primary
study end-points were achieved.
Study 003 – Phase I/II Rapid Infusion
UTI/Urosepsis I.V. Clinical Trial
R327 Intravenous (I.V.) formulation
Study 001 – Phase I I.V. Clinical Trial
Conducted at Adelaide's CMAX clinical trial facility,
the Company’s first-in-human Phase I clinical trial is
an ascending dose, randomised, placebo-controlled,
parallel, double-blind, single-dose study (Trial ID
ACTRN12621001313820).
Dosing has been completed, with a total of 80
healthy subjects intravenously dosed (60 with R327
and 20 with placebo) to evaluate the safety and
pharmacokinetics of R327. The Company completed
dosing of 8 Cohorts with a dose ceiling of 6,000mg,
a 120-fold increase on Cohort One (50mg dose).
No serious adverse events were observed in
subjects dosed with R327.
Following the completion of Phase I I.V. Clinical Trial
(Study 001), Australia’s HREC (Human Research
Ethics Committees) approved R327 to be evaluated
at faster infusion rates in both male and female
healthy subjects. Testing R327 in female subjects is of
utmost importance since women have a much higher
likelihood than men of developing UTI that could lead
to urosepsis. Post FY23 (10 July, 2023) the first cohort,
which included first female subject, was already
dosed successfully with 2,500mg of R327.
The Phase I/II trial is assessing R327 as an intravenous
dose at faster infusion rates across three cohorts
as a broad spectrum anti-infective to assess R327’s
potential as a treatment option in UTI/Urosepsis
across the patient infectious disease journey
(underlying infection>septic state) positioning
it for therapy in this area of unmet medical need.
On dosing days, plasma and urine will be collected
up to 24 hours post-dose to evaluate R327's
antibacterial properties.
UTI/UrosepsisOverview
Overview
UTI/Urosepsis
About half of women
and more than one in
10 men will get a
urinary tract infection
(UTI) in their lifetime.
Previous years have demonstrated the
likelihood of antibiotics killing most
UTIs is rapidly dropping.
What is Urosepsis?
Urosepsis is sepsis caused by infections
of the urinary tract. Urosepsis in adults
comprises approximately 20-30% of
all sepsis cases.
Ureter
Bladder
Urethra
Urinaty Tract Infection
is an infection in any part of the urinary
system. The most common UTI is
cystitis, which is an infection of the
bladder. Other UTIs involve the urethra
or kidneys.
404.6
MILLION
individuals had UTIs
in 2019 worldwide
75%
of the UTI cases
are caused by
Escherichia coli
80%
are resistant to at
least two antibiotics
92%
of bacteria that cause
UTIs are resistant to at
least one common
antibiotic
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
Kidney
Where Urinary Tract
Infection's can spread
Urosepsis
Although UTI is often uncomplicated
and easy to treat, sometimes bacteria can
infect your bloodstream. This condition
is called urosepsis, and it can be deadly.
9
Topical Programs
Study 101 – Phase I/II Topical Diabetic
Foot Infection Clinical Trial
Currently conducting the largest Diabetic Foot
Infection (DFI) Clinical Trial ongoing in Australia, the
Company has built out its topical broad-spectrum
bacterial infection treatment programs through a new
Phase I/II clinical trial for DFI at a leading Australian
teaching hospital.
NEW SOUTH WALES
The trial has expanded its clinical trial
sites
to multiple
SOUTH
AUSTRALIA
states, including CMAX Clinical Research (South
Australia) and Scientia Clinical Research (New South
Wales), allowing the study to be expedited and to
broaden the patient population across multiple
world class facilities.
Administering the drug at faster rates, especially
within a GP setting or an Acute patient setting, is
important as this allows the infection to be treated
more rapidly. The 2021 Surviving Sepsis Campaign
(SCC) guidelines strongly recommend that the
administration of intravenous broad-spectrum
antibiotics should be initiated as soon as possible,
preferably within an hour of sepsis recognition.
DFI Overview
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
10
60%
of the patients with
diabetes undergo
nontraumatic foot
amputations
85%
of the diabetesrelated amputations
precede foot
ulceration
28%
is the 3-year
cumulative
mortality rate
for DFU patients
The trial received Human Research Ethics Committee
approval to begin and will enrol up to 32 patients.
It will be conducted at Sydney South West’s Limb
Preservation and Wound Research Unit, located at
the Ingham Institute of Medical Research. This unit
was selected for its innovative and ground-breaking
focus on wounds of the limbs and limb loss, an underresearched area in Australian healthcare.
The Company is exploring R327 as a preventative
treatment for DFI, an ever-increasing problem in the
Western World and which leads to 25% of Diabetic
Foot Ulcer cases in the U.S. requiring amputation
at some point. Moreover, the total medical costs
for treating diabetic foot diseases in the U.S. are
estimated at US $9-13 billion every year.
DFI section
Diabetic Foot Infections
are a common complication
of diabetes that is not being
managed through methods
such as diet, exercise, and
insulin treatment. Ulcers
Diabetic
Foot Infections are
are formed as a result of
a common
complication of
skin tissue breaking down
diabetes
thatthe
is not
and exposing
layersbeing
managed
through
methods
underneath.
such as diet, exercise, and
insulin treatment. Ulcers
are formed as a result of
footdown
infection is
skin tissue Diabetic
breaking
one
of
the
common,
costly,
and exposing the layers
and
severe
complications
of
underneath.
diabletes.
Outpatient Nurses Appointed and Patient
Population Increased
The Phase I/II clinical trial of R327 is supported
by in-home nurses trained in R327 DFI treatment
protocols, broadening treatable DFI trial patient
population.
Services provided by Ascott nurses will be
adhering to national and international clinical
trial regulatory requirements
–
Collecting vital signs, conducting basic
wound assessment and cleaning
–
Administering R327 as a topical agent
–
Performing concomitant medicant and
adverse event monitoring and recording
Study 102 – Phase I/II Topical Burn Wound
Infection Clinical Trial
The Phase I/II Topical Burn Wound Infection Clinical
Trial has produced patient examples with multiple
bacterial species in and surrounding wound. Growth
swabs were taken and revealed to include pathogens
from the ESKAPE group of bacteria.
Pre-Clinical Programs
The Company has established an Anti-Infective
Research Unit (AIR Unit) located within the Murdoch
Children’s Research Institute, one of the top three
children’s research institutes worldwide, to accelerate
pre-clinical activities. Based in Melbourne, one of
the world’s most innovative cities for world-leading
medical research and development, the dedicated
research within Recce’s AIR Unit will streamline
ongoing pre-clinical programs and explore new
research development opportunities.
Targeted at discovering pre-clinical indications
with in-human clinical trial potential, the AIR Unit
will focus on advancing pre-clinical indications such
as M. abscessus and Bacterial Sinusitis. The unit is
equipped with fit-for-purpose laboratory space and
a dedicated Murdoch Children’s team with access to
a large bank of infectious disease strains and other
expertise.
Following treatment with R327, favourable
signs were observed including:
Healthy skin growth
Reduced swelling
Reduced infection
Indication of tissue
penetration to the side
of underlying infection
Murdoch Children’s Research Institute. Photo taken by John Gollings.
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
Recce is working to expand the number of domestic
and international clinical sites involved in this trial
with expected progress in FY 2024.
11
Conference Engagement
Key Events with Investors,
Key Opinion Leaders, and
Global Conferences
The Company has increased its
presence at global conferences
and interactions with Key Opinion
Leaders in order to increase
investment opportunities and
engagement within the sepsis and
antimicrobial resistance community.
See below the conferences the Company
participated in throughout the financial year:
2022
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
12
JP Morgan LifeSci Advisors Corporate Access Event
San Francisco, USA
Jul 2022
ASM Annual Scientific Conference
Sydney, AUS
Sep 2022
World AMR Congress
Washington DC, USA
Sepsis Alliance Summit
Virtual
Attendance at global investor and
industry events has allowed the
Company to expand its business
development programs, and network
with potential partners.
Recce also intensified its institutional
investor access throughout the
year, in particular the APAC Region,
Europe and the United States, aimed
at building long-term and broader
relationships.
Jan 2022
Sepsis Awareness Month
Virtual
2023
Oct 2022
ESCMID/ASM Conference on Drug Development –
Research Abstract and Poster Presentation
Dublin, Ireland
Feb 2023
High Net Worth Investor Event
Zurich, Switzerland
Mar 2023
High Net Worth Investor Event
Geneva, Switzerland
Wholesale Investor Emergence Sydney
Sydney, AUS
Wholesale Investor Emergence London
London, UK
Apr 2023
Sepsis Alliance AMR Conference
Virtual
May 2023
BIO Korea 2023
Seoul, South Korea
June 2023
BIO International Convention
Boston, USA
ASM Microbe
Houston, USA
Board of Directors and
Key Management Personnel
Dr John Prendergast
Executive Chairman
BSc (Hons), MSc (UNSW),
PhD (UNSW), CSS (HU)
James Graham
Managing Director and
Chief Executive Officer
BCom (Entrepreneurship), GAICD
Michele Dilizia
Executive Director and
Chief Scientific Officer
BSc (Med Sci), Grad Dip Bus (Mkting),
BA (Journ), GAICD, MASM
Dr Justin Ward
Executive Director and
Principal Quality Chemist
BSc (Chem), PhD (Chem),
MRACI, CChem, MPharm
Non-Executive Director
BSc (BioChem) Hons, M.D. (NYU)
Mr Graham is the Chief Executive Officer of Recce
Pharmaceuticals. He was formerly Executive Director and has
extensive experience in marketing, business development
and commercialisation of early-stage technologies with
global potential. Mr Graham has served on Recce’s Board of
Directors for six years and has invested in almost every capital
raise to date with a focus on expanding Recce’s commercial
opportunities and clinical initiatives.
Ms Dilizia is a co-inventor and qualified medical scientist
with a specialisation in medical microbiology and regulatory
affairs. She successfully co-led the research and development
of Recce’s suite of anti-infective compounds, resulting in a
portfolio of granted patents across the globe, including a
Qualified Infectious Disease Product designation with the
U.S. Food and Drug Administration (FDA).
Dr Ward is a qualified Chemist and Pharmacist with over
20 years of pharmaceutical and biotech industry experience
in quality control, quality assurance, product research and
development with leading pharmaceutical companies,
including Pfizer. Dr Ward previously held a technical role
with Pfizer, involving providing data for regulatory
submissions to the FDA and TGA.
Based in the US, Dr Dunton is Director of Palatin
Technologies. He has over three decades of senior
pharmaceutical experience including as President and
MD of Janssen Research Foundation (Johnson & Johnson).
Dr Dunton has advanced approximately 20 blockbuster drugs
through regulatory review and commercialisation at Fortune
500 companies including Roche.
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
Dr Alan Dunton
Based in the US, Dr Prendergast is the current Chairman and
Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and
Lead Director of Nighthawk Biosciences (NYSE: HHWK). With
extensive experience in the international commercialisation
of pharmaceutical technologies, Dr Prendergast has been
responsible for the approval of three new drug applications.
13
Alistair McKeough
Non-Executive Director
(Prandium Capital)
Arthur Kollaras
Principal Engineer & Head
of Manufacturing
BSc, BEng (Chem), PhilEng (Enviro),
MIEAust, MISPE
Justin Reynolds
Chief Financial Officer
(Pitcher Partners)
Maggie Niewidok
Company Secretary
(Kardos Scanlan)
Daniel Astudillo
Head of Marketing
BCom (Marketing), BA (Spanish), MBA
RECCE PHARMACEUTICALS ANNUAL REPORT 2023
14
Thomas Jarrett
Operations Manager
BSc (Bioengineering)
Mr McKeough is an experienced executive and solicitor.
Before being appointed as a non-executive director in
2022, Alistair served as Recce’s company secretary and
he has been involved with the company since 2017. Alistair
has extensive experience in a variety of private and listed
corporations across many sectors, including professional
services, technology, financial services, charities, health,
biotech, childcare and education. Recent roles include
Managing Director of a legal practice specialising in equity
Share your feedback
Discover